You are now leaving this website.
Are you sure?
NO
YES

The Kedrion portfolio of plasma-derived therapies addresses a range of disorders and conditions from Albumin for critical care to Rh0(D) Immune Globulin (human) to prevent hemolytic disease of the fetus and newborn. 

Our continuing commitment to research, development and innovation, along with our growing industrial capacity and expanding international market presence, contributes to an ever-greater access to effective healthcare for people suffering these debilitating conditions.

Our Therapeutic Areas include: